H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress By Investing.com

Legend Biotech reported Q4 revenues of about $306 million, ahead of the $288 million estimate, with EPS of $(0.08) versus $(0.10) expected. The company’s share of Carvykti sales reached $306.3 million in Q4 and $1.03 billion for full-year 2025, while Johnson & Johnson reported Q1 2026 worldwide Carvykti sales of $597 million. H.C. Wainwright reiterated a Buy rating and $50 target, and shares have risen nearly 20% over the past week on continued CAR-T momentum.

Analysis

LEGN is transitioning from a “story stock” into a cash-flow duration trade: the market is likely still underestimating how quickly commercial momentum can compound once a CAR-T franchise clears the early adoption hump. The key second-order effect is that stronger order-book visibility reduces the probability of a post-approval air pocket, which is what usually compresses multiples in cell therapy names after the first enthusiasm burst.

The real signal here is not just product traction, but mix shift. If the fastest-growing segments continue to migrate earlier in the treatment algorithm, the revenue base becomes less dependent on late-line volatility and more on institutional pathway adoption, which tends to be sticky once hospitals operationalize capacity. That supports multiple expansion over the next 2-3 quarters, especially if upcoming data de-risks the platform narrative beyond a single product.

The main contrarian risk is that the stock has already re-rated quickly, so the next leg higher likely requires a catalyst, not just “good enough” execution. In biotech, this kind of setup is vulnerable to the classic disappointment trade: if the imminent readout is incremental rather than clearly best-in-class, momentum longs can unwind fast, even if fundamentals remain intact. IQV noise suggests end-market health is better than the tape implies, but that also means traders may be over-assigning cyclical explanations to what is really a sequencing issue.

For JNJ, the asymmetry is modestly positive because any confirmation of broader CAR-T adoption reinforces an underappreciated growth pocket inside an otherwise defensive conglomerate. The bigger winner may be the ecosystem around cell therapy manufacturing and site enablement, but absent direct exposure, this remains a LEGN-specific catalyst with JNJ as a secondary beneficiary rather than the trade itself.

Key Decisions for Investors

• Long LEGN into the next major data/readout window over the next 4-8 weeks; use a tight downside stop because the stock has already moved ~20% in a week and a merely adequate update could trigger a sharp de-rating.
• Buy LEGN call spreads expiring after the expected presentation window; structure for upside continuation while limiting premium bleed if the catalyst slips or underwhelms.
• If already long, trim 20-30% into strength and hold the remainder for the readout: the risk/reward has shifted from pure momentum to catalyst dependence.
• Consider a pair trade: long LEGN / short an unprofitable small-cap biotech basket over 1-3 months, betting that platform de-risking and revenue visibility will keep LEGN’s multiple supported relative to funding-sensitive names.
• Use JNJ only as a low-beta secondary expression: small long JNJ vs short broader healthcare if you want modest participation in CAR-T adoption without taking single-name biotech event risk.